The company said worldwide revenue for fiscal 2025 Q2 (ended October 25, 2024) was $8.403 billion, up 5.3% as reported and 5.0% on an organic basis.

1. 01

   The company said worldwide revenue for fiscal 2025 Q2 (ended October 25, 2024) was $8.403 billion, up 5.3% as reported and 5.0% on an organic basis.

2. 02

   Medtronic said GAAP diluted EPS for Q2 was $0.99 (net income of $1.270 billion, up 40% and 46%, respectively), and non-GAAP diluted EPS was $1.26 (non-GAAP net income of $1.620 billion, down 3%, and EPS up 1%).

3. 03

   The company raised its fiscal 2025 organic revenue growth guidance to 4.75% to 5% from the prior 4.5% to 5%, and its non-GAAP diluted EPS guidance to $5.44 to $5.50 from the prior $5.42 to $5.50, it said.

4. 04

   Medtronic reported free cash flow of $1,020 million for the first half of fiscal 2025 (6 months ended October 25, 2024), calculated as operating cash flow of $1,944 million less capital expenditures of $924 million.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.